The board chairman and CEO of Genix Therapeutics, in Wheeling, Illinois, Ragab El-Rashidy has been instrumental in marketing and developing UPRIMA, a medicine that treats impotence. Previously available only in Japan and parts of Europe, Ragab El-Rashidy's efforts have secured its release in the United States. El Rashidy has also founded three companies that researched sexual dysfunction products; to these firms he brought experience with financing and fund raising, bringing in $25 million in grants for clinical trials.
Research into this treatment and its delivery systems began at Pharmedic Laboratories, Inc., where El-Rashidy served as CEO, director, and board chairman. Prior to this experience, he was the director of research and development at Gynex, Inc., where he consulted with upper management on regulatory, clinical, and budget issues.
Previously, El-Rashidy worked at Baxter Travenol International, where he guided the development of new delivery systems and filed patents for proteins and biotechnology discoveries. Before then, he coordinated with various research projects at G. D. Searle and Company.
After graduating from the University of Illinois in Chicago with a doctorate in clinical pharmacokinetics and biopharmaceutics, Ragab El-Rashidy became a senior scientist at Alcon, Inc., where he investigated the properties of drugs in development for diseases of the eye.